http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190040764-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cc79ee5ce95c471238634548dbc14b3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98a5671904c4599e077e12afdd26b409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b360fce54d37902940fce6282eb6d6ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_804ab453ecd924565b60c0648d392db0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf28904d67924910620f7154a329f543 |
| publicationDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20190040764-A |
| titleOfInvention | Pharmaceutical formulation comprising Ticagrelor and preparation method thereof |
| abstract | The present invention relates to a pharmaceutical composition comprising tikageler, and more particularly to a pharmaceutical composition comprising a tikagreler as an active ingredient and at least one pharmaceutical excipient, Wherein at least 90% of the total weight of the active ingredient is eluted at the time of 30 minutes to 90 minutes from the start of the test in the dissolution test. The pharmaceutical composition comprising the ticagrella of the present invention as an active ingredient is a preparation for improving the solubility of ticagrella known as a poorly soluble drug, in which the active ingredient is released in an amount of 90% or more within 30 minutes to 90 minutes, The pharmacokinetic results can be obtained and the formulation can be developed to increase the compliance of patients. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023149642-A1 |
| priorityDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.